In adult BCR/ABL negative ALL, the indication of allogeneic HSCT will be determined by the MRD status. High-risk patients will proceed to allogeneic HSCT. Low-risk patients will proceed to maintenance

3 trials

Sponsors

Akashi Koichi, Fukuoka Blood & Marrow Transplant Group

Conditions

acute lymphoblastic leukemiaadult acute lymphocytic leukemia

Phase 2

Treatment protocol for adult acute lymphocytic leukemia -ALL/ MRD2008-

Active, not recruitingJPRN-UMIN000001519

Fukuoka Blood & Marrow Transplant Groupadult acute lymphocytic leukemia

Start: 2008-12-01Target: 20Updated: 2026-06-29

Treatment protocol for adult acute lymphoblastic leukemia -ALL/MRD2014-

Active, not recruitingJPRN-UMIN000012382

Fukuoka Blood & Marrow Transplant Groupacute lymphoblastic leukemia

Start: 2014-02-16Target: 100Updated: 2026-06-29

Treatment protocol for adult acute lymphoblastic leukemia

Active, not recruitingJPRN-jRCTs071190036

Akashi Koichiacute lymphoblastic leukemia

Start: 2020-01-07Target: 200Updated: 2026-06-29

Related Papers

Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With <i>BCR::ABL1</i> Acute Lymphoblastic Leukemia: Result of the Prospective <scp>MRD2014</scp> Study Conducted by Fukuoka Blood and Marrow Transplantation Group (<scp>FBMTG</scp>)

European Journal Of Haematology2025-03-07

Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study.

2024-08-01

Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph‐negative acute lymphoblastic leukemia

European Journal Of Haematology2019-05-2712 citations